ARTICLE | Company News
BioNTech, 4SC deal
December 24, 2012 8:00 AM UTC
4SC's 4SC Discovery GmbH subsidiary granted BioNTech exclusive, worldwide rights to develop and commercialize 4SC's preclinical small molecule toll-like receptor (TLR) agonists to treat cancer. 4SC wi...